- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Melanoma Activist
Chicago - An orally active small molecule inhibitor of Raf kinase, the first of its class to enter clinical trials, is well tolerated when combined with standard chemotherapy agents, and may have activity against metastatic melanoma, Keith T. Flaherty, M.D., said at the annual meeting of the American Society of Clinical Oncology.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
Case 2: Poorly Managed GPP Flares and Effisayil 2 Trial Results
Case 1: Experts on a GPP Emergency Case and Effisayil 1 Trial Results
Long-Term Efficacy and Safety of IL-17 Inhibitors in Psoriasis
Determining Appropriate Candidates for JAK Inhibitor Therapy
Enhancing Treatment Adherence: The Impact of Convenience and Topical JAK Inhibitors on Real-World Outcomes
Potential Role of Ruxolitinib Cream in Managing Pediatric Atopic Dermatitis: A Perspective on Use in Ages 2–11
The Need for Nonsteroidal Alternatives in Long-Term Atopic Dermatitis Care: A Focus on Pediatric Patients
Parental Frustrations with Current Treatment Options for Children with Atopic Dermatitis
Navigating Patient Factors When Deciding Treatment for a 38-Year-Old Woman With Severe Atopic Dermatitis
Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis
Related Content
